Navigation Links
Novel aspects of histamine research discussed in Versita open access book
Date:11/13/2013

Histamine H4 Receptors: A novel Drug Target for Immunomodulation and Inflammation, edited by Professor Holger Stark, is a new Open Access Book comprising key results from the highly acclaimed Action BM0806, held by COST (European Cooperation in Science and Technology), which was instituted to champion and promote a multidisciplinary approach to H4R research, and focused on the current state of play pertaining to the basic understanding and the huge therapeutic potential of this new drug target. The objective of this project was to advance awareness of the newly identified histamine receptor.

The book describes molecular signaling mechanism, the function as well as the localization of this receptor subtype, along with its influence on physiological and pathophysiological properties. It offers an insight into a range of perspectives on H4R research, and a thorough analysis of the possibilities for novel therapeutic inventions and exploitation, allowing for newly designed compounds as well as numerous biochemical in vitro and in vivo models on different species.

Chapter by chapter, different aspects of histamine research are presented and discussed. The contributing authors were all active members of Action BM0806 and as a result, the book covers the most original and topical aspects of histamine research. One of them is the role of histamine in allergic reactions, which was assumed to have been clarified for many decades. Presently, the increased understanding of histamine and its functions places it at the centre stage in the orchestration of the innate immune response and lead-up to the adaptive response. Professor Madeleine Ennis (Secretary, COST Action BM0806) and colleagues discuss in detail the evidence for the roles of various histamine receptors (particularly the H4R) in immune cell function, spanning eosinophils, monocytes, basophils, mast cells and neutrophils. Another newsworthy section, dedicated to histamine and cancer, is written
'/>"/>

Contact: Maria Hrynkiewicz
maria@versita.com
48-660-476-421
Versita
Source:Eurekalert  

Page: 1 2

Related biology news :

1. Novel LEDs pave the way to cheaper displays
2. Novel technique for suturing tissue-engineered collagen graft improves tendon repair
3. Novel mutations define 2 types of bone tumor
4. NIH funds development of novel robots to assist people with disabilities, aid doctors
5. Mutations in novel tumor suppressor gene associated with early onset breast cancer
6. IRICoR and Université de Montréal license a novel program for early-onset morbid obesity to Pfizer
7. Novelty of eco-friendly bamboo garments lures consumers -- if the price is right, Baylor study shows
8. Novel mechanism discovered in first line of immune defense
9. Novel avian influenza A virus has potential for both virulence and transmissibility in humans
10. Researchers develop novel polymer to help oral medications reach the bloodstream
11. Novel approach to gene regulation can activate multiple genes simultaneously
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Novel aspects of histamine research discussed in Versita open access book
(Date:7/9/2015)... July 07, 2015 ... addition of the "Biometrics for Banking; Market ... report to their offering. The ... to this growth and the forecast is that ... revenue for companies involved in delivering biometric systems ...
(Date:7/9/2015)... 9, 2015  Synaptics Inc. (NASDAQ: ... interface solutions, today announced a new Match-in-Sensor™ ... hardware encapsulated fingerprint sensor and matching solution. ... literally off the grid, isolating fingerprint image ... the fingerprint sensor to provide ultimate protection ...
(Date:7/8/2015)... , N.J. and NEW YORK , ... and Guidepoint today announced BD & ... healthcare companies with free access to Guidepoint,s expert network ... start-ups that are developing cutting-edge technologies to improve healthcare ... dedicated Guidepoint research manager, each start-up entrepreneur will be ...
Breaking Biology News(10 mins):Global Banking Biometrics Market 2015-2020 - Market & Technology Analysis, Adoption Strategies and Forecasts 2Global Banking Biometrics Market 2015-2020 - Market & Technology Analysis, Adoption Strategies and Forecasts 3Synaptics Announces World's First Match-in-Sensor Fingerprint Authentication Technology 2Synaptics Announces World's First Match-in-Sensor Fingerprint Authentication Technology 3BD and Guidepoint Team to Connect Healthcare Start-up Companies With Business and Scientific Experts 2BD and Guidepoint Team to Connect Healthcare Start-up Companies With Business and Scientific Experts 3
... the battle against AIDS and a major development in the ... protein that prevents the virus from entering cells. This protein ... that protects cells from viruses, except the man-made version does ... needed to inhibit AIDS. This discovery was published in the ...
... Reducing Emissions from Deforestation and Forest Degradation ... that aims to financially compensate landowners and stewards ... as promoting forest conservation, sustainable forest management and ... and implemented correctly, REDD+ has the potential to ...
... RIVERSIDE, Calif. What are transposable elements, what role do ... they comprise? Is there an explanation for the genetic diversity ... spotted? What is the genetic basis for this spotted trait? ... a free public lecture at 6 p.m., Thursday, April 14, at ...
Cached Biology News:Intelligent design: Engineered protein fragment blocks the AIDS virus from entering cells 2REDD+, Technical, Socioeconomic and Political Dimensions 2REDD+, Technical, Socioeconomic and Political Dimensions 3Teaching old genomes new tricks 2
(Date:7/30/2015)... July 30, 2015 AACC welcomed thousands ... 2015 AACC Annual Meeting & Clinical Lab Expo ... 26–30. The meeting showcased revolutionary advancements in clinical ... of healthcare providers to diagnose patients quickly and ... treatment. As of Wednesday, July ...
(Date:7/30/2015)... , ... July 30, 2015 , ... The 2015 Market ... study on the current state of the global Propanol market with a focus on ... BASF, Eastman, Dow, Carboclor, Mitsui Chemicals, Oxea, ISU Chemical, Sanofi, Royal Dutch Shell, LG ...
(Date:7/30/2015)... Kan. , July 30, 2015   ... a pet therapeutics company focused on the licensing, ... companion animals, today announced that its strategic partner ... a dose confirmation study of AT-016, an adipose-derived ... for the treatment of osteoarthritis pain in dogs. ...
(Date:7/30/2015)... COPENHAGEN, Denmark , July 30, 2015 /PRNewswire/ ... a biotechnology company that applies its innovative TransCon ... announced positive top-line results from a six-month Phase ... of once-weekly TransCon Growth Hormone in 53 treatment-naïve, ... "We are extremely pleased with the ...
Breaking Biology Technology:Innovative Research on Cancer, Heart Disease, and Infectious Diseases Draws More than 17,500 Attendees to 2015 AACC Annual Meeting 2Innovative Research on Cancer, Heart Disease, and Infectious Diseases Draws More than 17,500 Attendees to 2015 AACC Annual Meeting 3Innovative Research on Cancer, Heart Disease, and Infectious Diseases Draws More than 17,500 Attendees to 2015 AACC Annual Meeting 4Global Propanol Market Technical Data and Manufacturing Analysis 2020 2Global Propanol Market Technical Data and Manufacturing Analysis 2020 3Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 2Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 3Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 4Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 5Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 2Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 3Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 4Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 5Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 6Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 7
... HUYA Bioscience International, a leader in globalizing ... the Shenzhen Polytechnic School of Applied Chemistry and Biotechnology ... in accelerating the development of novel drugs, discovered from ... The agreement provides HUYA with access to and ...
... NephroGenex, Inc., a privately held drug development company, ... the FDA on the design of a new Phase ... nephropathy patients.  This Subpart H program uses a novel ... (SCr), and provides for an accelerated regulatory pathway to ...
... Halozyme Therapeutics, Inc. (NASDAQ: HALO ), a ... extracellular matrix for the diabetes, cancer, dermatology and ... third quarter of 2011 and discussed recent business progress. ... past few months highlight the progress at Halozyme on ...
Cached Biology Technology:HUYA Bioscience International Builds Long-Term Relationship with Shenzhen Polytechnic School of Applied Chemistry and Biotechnology 2HUYA Bioscience International Builds Long-Term Relationship with Shenzhen Polytechnic School of Applied Chemistry and Biotechnology 3NephroGenex Reaches Agreement with the FDA on a Subpart H Phase 3 Program for Pyridorin™ 2Halozyme Therapeutics Reports Third Quarter 2011 Financial Results 2Halozyme Therapeutics Reports Third Quarter 2011 Financial Results 3Halozyme Therapeutics Reports Third Quarter 2011 Financial Results 4Halozyme Therapeutics Reports Third Quarter 2011 Financial Results 5Halozyme Therapeutics Reports Third Quarter 2011 Financial Results 6Halozyme Therapeutics Reports Third Quarter 2011 Financial Results 7
...
Anti-MMP-7, aminoterminal end active enzyme; rabbit host...
Mouse monoclonal [CLB-SW16 (formerly 708)] to CD42d (rating: ****) ( Abpromise for all tested applications). entrezGeneID: 2814 SwissProtID: P40197...
Mouse monoclonal [7C6] to Bcr-abl ( Abpromise for all tested applications). SwissProtID: P11274...
Biology Products: